Cagrilintide is a 37-amino-acid acylated amylin analog with affinity at all five amylin receptor subtypes. Investigated by Novo Nordisk both as monotherapy and in combination with semaglutide (CagriSema).
Cagrilintide is a long-acting, acylated analog of amylin — the pancreatic hormone co-secreted with insulin that signals satiety and slows gastric emptying. It binds across the amylin and calcitonin receptor subtypes and carries a fatty-acid chain that supports once-weekly dosing.
Developed by Novo Nordisk, it is investigational and studied both on its own and in a fixed combination with semaglutide known as CagriSema, where the amylin and GLP-1 pathways are paired for additive weight effect.
Amylin and calcitonin receptor agonism → satiety, slowed gastric emptying.
Behind every vial of Cagrilintide is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how Cagrilintide, specifically, is brought into being.
On paper, Cagrilintide is C194H312N54O59S2 — about 4,409.2 daltons of precisely arranged atoms. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.
Cagrilintide is assembled by solid-phase peptide synthesis — the chain grows one protected residue at a time on resin, and what you fail to build cleanly here you pay to remove later. It also carries fatty-acid acylation, an extra step beyond a plain chain that adds both capability and cost.
The crude mixture — Cagrilintide plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one.
A real batch of Cagrilintide proves itself: identity confirmed by mass spectrometry against its ~4,409.2 Da, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of Cagrilintide — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.
Producing Cagrilintide to a genuine purity spec means solid-phase synthesis, preparative HPLC purification, and batch quality control — none of it cheap, and none of it something you can verify by eye.
Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.
Cagrilintide is an investigational long-acting amylin analog studied for weight management, both alone and combined with semaglutide (CagriSema).
CagriSema is the investigational fixed combination of cagrilintide (amylin) and semaglutide (GLP-1), pairing two appetite pathways for additive effect.
Both promote satiety, but amylin acts through amylin and calcitonin receptors while GLP-1 acts through the GLP-1 receptor; combining them is studied for complementary effects.
No — it is investigational. This page is a research and educational reference.